Protalix CFO to Outline Rare Disease Pipeline at September Conferences
Gilad Mamlok, the Chief Financial Officer of Protalix BioTherapeutics, will head to New York City next week to represent the biopharmaceutical firm at two major industry gatherings. The executive plans to address investors on the company’s current portfolio of rare disease therapies and its ongoing clinical development programs.
Mamlok is scheduled to deliver a formal presentation at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 2:00 p.m. EDT. Two days later, he will participate in a fireside chat during the Morgan Stanley 24th Annual Global Healthcare Conference, starting at 1:05 p.m. EDT. The company noted that a live audio webcast of the Morgan Stanley session will be accessible via their official investor portal, with an archived replay offered shortly after the event concludes.
Based in Carmiel, Israel, Protalix focuses on plant cell-based protein expression. Their commercial footprint currently includes Elfabrio, a treatment for Fabry disease developed with Chiesi Global Rare Diseases, and Elelyso, a therapy for Gaucher disease marketed alongside Pfizer. Beyond these approved products, the company is advancing its pipeline with PRX-115, currently in Phase 2 trials for uncontrolled gout, and PRX-119, designed to treat NETs-related conditions.
Comments (0)
No comments yet. Be the first!